ArticleClinical and experimental medicine2025
High NUP210 mRNA expression and its role in prognosis of acute myeloid leukemia.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pathologies at the gateway: exploring the link between nucleoporins and inherited diseases.Cellular and molecular life sciences : CMLS · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Acute myeloid leukemia (AML) is the most prevalent type of leukemia in adults, characterized by a complex pathogenesis. The nuclear pore complex is pivotal in the development of various of malignant tumors, including hematological malignancies. While the NUP210 gene is upregulated in several solid tumors, its role in AML remains unreported. RNA-Sequence data and clinical profiles of AML patients were obtained from TCGA databases. Bone marrow samples were obtained from the First Affiliated Hospital of Ningbo University. GEPIA2, UALCAN and TCGA Portal databases were employed for survival prognosis analysis based on NUP210 expression. The GO/KEGG enrichment analysis of NUP210 co-expression and GSEA were performed using R software package. ENCORI and STRING databases were utilized to validate the association between NUP210 and MEIS1, PBX3 or HOXAs. CCK8, RT-qPCR, and Western blot assays were used to detect the viability and related gene expression in AML cell lines.Our findings revealed that NUP210 was significantly upregulated in AML patients compared to healthy controls. Multivariate analyses identified NUP210 as an independent poor prognostic factor in AML. Increased expression of NUP210 inhibited the viability of AML cells. The HOXA9, MEIS1, and PBX3 genes were notably upregulated in the NUP210 high-expression group. The RT-qPCR and Western blot assays demonstrated that NUP210 downregulation in leukemia cells leads to the inhibition of HOXA9 expression. Positive correlations were observed between NUP210 and MEIS1/PBX3, with MEIS1 and PBX3 proteins interacting with the HOXA9 protein. Our results demonstrated that NUP210 was remarkably upregulated in AML and may promote the malignant behavior of AML cells by upregulate HOXA9 gene expression, offering new insights for AML treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.